Clarkston Capital Partners LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 322,446 shares of the company’s stock after buying an additional 16,594 shares during the period. Johnson & Johnson comprises 1.9% of Clarkston Capital Partners LLC’s investment portfolio, making the stock its 19th largest position. Clarkston Capital Partners LLC’s holdings in Johnson & Johnson were worth $40,161,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the stock. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $3,220,322,000. Asset Management One Co. Ltd. boosted its stake in shares of Johnson & Johnson by 1,147.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 4,946,229 shares of the company’s stock worth $569,967,000 after buying an additional 4,549,711 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $277,294,000. Renaissance Technologies LLC boosted its stake in shares of Johnson & Johnson by 132.1% in the fourth quarter. Renaissance Technologies LLC now owns 3,423,100 shares of the company’s stock worth $394,375,000 after buying an additional 1,948,000 shares during the last quarter. Finally, Elkfork Partners LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $114,861,000. Institutional investors own 66.10% of the company’s stock.
Johnson & Johnson (JNJ) traded down 0.31% on Friday, hitting $132.63. The stock had a trading volume of 4,792,761 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The firm’s 50-day moving average price is $132.88 and its 200-day moving average price is $127.04. The firm has a market cap of $355.98 billion, a P/E ratio of 22.44 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.74 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
TRADEMARK VIOLATION WARNING: “Clarkston Capital Partners LLC Acquires 16,594 Shares of Johnson & Johnson (NYSE:JNJ)” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/19/clarkston-capital-partners-llc-boosts-position-in-johnson-johnson-nysejnj-updated-updated-updated.html.
JNJ has been the subject of a number of research reports. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC reiterated a “hold” rating and set a $135.00 target price (down previously from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Royal Bank Of Canada restated a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a report on Friday, July 21st. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and an average price target of $134.12.
In related news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
